Cytomegalovirus (CMV) resistance to antivirals.
This article reviews the biology of cytomegalovirus (CMV), the approved antiviral therapies, and mechanisms of resistance to these drugs. The rates of resistance development in clinical trials are presented, as are the assays for testing susceptibility by phenotypic and genotypic methods. Factors that favor the development of clinical and in vitro antiviral resistance are discussed. Finally, approaches to altering antiviral therapy as resistance develops are outlined.
Drew
W L
WL
Department of Laboratory Medicine, UCSF Mt. Zion Medical Center, San Francisco, CA, USA. Lawrence.Drew@clinlab.ucsfmedctr.org
Paya
C V
CV
Emery
V
V
D000998:Antiviral Agents / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000187:drug effects / Q000235:genetics*; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D024882:Drug Resistance, Viral; D015774:Ganciclovir / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009154:Mutation
D000998:Antiviral Agents; D015774:Ganciclovir